Lupin in advanced talks to sign $1.5 billion deal with Merck Serono: Report

15 Sep 2014 Evaluate

Pharmaceutical major Lupin is reportedly in advanced talks to sign a blockbuster deal with Merck Serono. According to the deal, Lupin will manufacture Merck Serono’s $1.5 billion worth branded mature drugs at its facilities.

Moreover, the company will also get marketing rights for the drugs for emerging countries and European markets. Merck Serono will retain the rights to market these drugs in the developed markets.

Recently, Lupin entered into definitive distribution agreement with Salix Pharmaceuticals under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2178.20 1.95 (0.09%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×